Docetaxel: Response in patients who have received at least two prior chemotherapy regimes for metastatic breast cancer

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 816-819

  Archer, C D ^a   Lowdell, C ^b   Sinnett, H D ^b   English, J ^a   Khan, S ^a   Coombes, R C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Docetaxel; Metastatic breast cancer

Indexed keywords

DOCETAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; EDEMA; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; TREATMENT INDICATION;

EID: 0032078891     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10113-7     Document Type: Article

References (13)

1. Mourisden HT. Systemic therapy of advanced breast cancer. Drugs 1992, 44(Supp. 4), 17-28.
2. Bissery MC, Guenard D, Gueritte-Voegelein F et al. Experimental antitumour activity of Taxotere (RP. 56976.NSC 628503), a Taxol analogue. Cancer Res 1991, 51, 4845-4852.
3. Piccart MJ. Taxotere: a second generation taxoid compound. In: ASCO Education Book, Twenty-Ninth Annual Meeting. Orlando, FL, Bostrom, 1995, 25-32.
4. Hudis CA, Seidman AD, Crown JPA, et al. Phase 2 and pharmacologie study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14, 58-65.
5. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996, 14, 422-428.
6. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Co-operative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995, 13, 314-322.
7. Bokkel Huinink WW ten, Prove AM, Piccart M, et al. A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994, 5, 527-532.
8. Ravdin PM, Burriss III HA, Cook G, et al. Phase II trial of Docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995, 13, 2879-2885.
9. Valero V, Holmes FA, Walters RS, et al. Phase II trial of Docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, 13, 2886-2894.
10. Miller AB, Hoogstratten B, Stagnet M, et al. Reporting results of cancer treatment. Cancer 1981, 47, 2507-2514.
11. Bonneterre J, Misset JL, Guastalla JP, et al. Feasibility and safety of taxotere (TXT) in heavily pre-treated metastatic breast cancer (MBC): preliminary report of a multicentre compassionate use program. Proc. ASCO 1996, no. 130.
12. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Er J Cancer 1996, 73, 210-216.
13. Dieras V, Chevallier B, Kerbat P, et al. A multicentre phase II study of Docetaxel 7 5 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 1996, 74, 650-656.